Position in COGT
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$1,034,838
+$182,670 QoQ
Shares Held
26,740
+20.8% QoQ
Ownership
0.015%
of shares outstanding
% of Portfolio
0.72%
of 13F equity value
Holder Rank
#191
of 321 holders
Holding Since
Mar 2021
10 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in COGT Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026SECTORAL ASSET MANAGEMENT INC holds $69,797,747 across 47 Biotechnology names. COGT ranks #20 (1.5% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | CTNM |
Contineum Therapeutics, Inc.
|
727,587 | $11,925,150 | |
| 2 | ORKA |
Oruka Therapeutics, Inc.
|
41,987 | $3,995,902 | |
| 3 | BNTX |
BioNTech SE
|
41,869 | $3,895,910 | |
| 4 | DFTX |
Definium Therapeutics, Inc.
|
78,310 | $3,683,702 | |
| 5 | RCUS |
Arcus Biosciences, Inc.
|
110,870 | $3,418,122 | |
| 6 | SMMT |
Summit Therapeutics Inc.
|
220,180 | $3,208,022 | |
| 7 | AVBP |
ArriVent BioPharma, Inc.
|
79,043 | $2,745,953 | |
| 8 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
5,432 | $2,698,237 |
All Filings in COGT
Export CSV
10 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1,034,838 | 26,740 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $852,168 | 22,140 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $1,160,971 | 32,685 | Shares | Sole | 2026-02-09 | |
| 2025-03-31 | $473,329 | 79,020 | Shares | Sole | 2025-05-15 | |
| 2024-12-31 | $575,640 | 73,800 | Shares | Sole | 2025-02-14 | |
| 2024-09-30 | $911,520 | 84,400 | Shares | Sole | 2024-11-14 | |
| 2024-06-30 | $721,608 | 85,600 | Shares | Sole | 2024-08-13 | |
| 2024-03-31 | $1,772,064 | 263,700 | Shares | Sole | 2024-05-14 | |
| 2021-06-30 | $218,970 | 27,000 | Shares | Sole | 2021-08-16 | |
| 2021-03-31 | $237,060 | 27,000 | Shares | Sole | 2021-05-14 | |
| No filing history on record for this holder in this stock. | ||||||